Skip to Content

Stryker Corp SYK

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Stryker Leans on Medsurg and Neurotech in Third Quarter; No Change to Our FVE

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

Stryker delivered a strong third quarter, helped along by the addition of Wright Medical, but softness in orthopedics led the firm to pull back on its outlook for the full year, causing shares to bobble in after-hours trading. We stick with our $190 fair value estimate, as our slight revisions to reflect further delays in orthopedic procedure volume in the near term weren’t enough to materially shift our valuation. Further, the firm remains on track with cost controls to meet our projections on the bottom line for the full year. The weakness in orthopedics and spine were more than offset by strong organic growth in medsurg and neurotech, which underscores the strength of Stryker’s wide moat, in our view. Aside from its formidable position in orthopedics, Stryker also has a long track record of generating meaningful innovation in its instruments, patient transportation, embolic coils, and thrombectomy systems for stroke patients. All of that adds to its well of intangible assets, and we surmise there may also be some switching costs associated with the stroke devices and delivery systems.

Read Full Analysis

Company Profile

Business Description

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one fourth of Stryker's total revenue currently comes from outside the United States.

2825 Airview Boulevard
Kalamazoo, MI, 49002
T +1 269 385-2600
Sector Healthcare
Industry Medical Devices
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type Classic Growth
Employees 43,000